Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of total docetaxel from a lipid microsphere formulation in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 926, Issue , 2013, Pages 101-107

  Du, Ping ^a   Li, Ning ^a   Wang, Hongyu ^a   Yang, Sheng ^a   Song, Yuanyuan ^a   Han, Xiaohong ^a   Shi, Yuankai ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Docetaxel lipid microsphere; Human plasma; Pharmacokinetics; UPLC MS MS

Indexed keywords

DOCETAXEL; ELECTROSPRAY IONIZATION (ESI); HUMAN PLASMAS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOWER LIMIT OF QUANTIFICATIONS; MULTIPLE REACTION MONITORING; RELATIVE STANDARD DEVIATIONS; UPLC-MS/MS;

ELECTROSPRAY IONIZATION; EMULSIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROSPHERES; PHARMACOKINETICS; PLASMA (HUMAN);

DRUG PRODUCTS;

DOCETAXEL; MICROSPHERE; PACLITAXEL;

ARTICLE; CALIBRATION; DILUTION; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ELECTROSPRAY; FLOW RATE; HUMAN; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRIORITY JOURNAL; REPRODUCIBILITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALIBRATION; CHROMATOGRAPHY, LIQUID; HUMANS; LIMIT OF DETECTION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TAXOIDS;

EID: 84876028958     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.02.006     Document Type: Article

References (19)

1. Bissery M., Guénard D., Guéritte-Voegelein F., Lavelle F. Cancer Res. 1991, 51:4845.
2. Douillard J., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., Liao M., Bischoff H., Reck M., Sellers M.V., Watkins C.L., Speake G., Armour A.A., Kim E.S. J. Clin. Oncol. 2010, 28:744.
3. Baker S.D., Verweij J., Cusatis G.A., van Schaik R.H., Marsh S., Orwick S.J., Franke R.M., Hu S., Schuetz E.G., Lamba V., Messersmith W.A., Wolff A.C., Carducci M.A., Sparreboom A. Clin. Pharmacol. Therap. 2008, 85:155.
4. van Waterschoot R.A.B., Lagas J.S., Wagenaar E., Rosing H., Beijnen J.H., Schinkel A.H. Int. J. Cancer 2010, 127:2959.
5. Baker S.D., Zhao M., He P., Carducci M.A., Verweij J., Sparreboom A. Anal. Biochem. 2004, 324:276.
6. Loos W.J., Baker S.D., Verweij J., Boonstra J.G., Sparreboom A. Clin. Pharmacol. Therap. 2003, 74:364.
7. Hennenfent K.L., Govindan R. Ann. Oncol. 2006, 17:735.
8. Singh M., Ravin L.J. PDA J. Pharm. Sci. Technol. 1986, 40:34.
9. Yamaguchi H., Fujikawa A., Ito H., Tanaka N., Furugen A., Miyamori K., Takahashi N., Ogura J., Kobayashi M., Yamada T., Mano N., Iseki K. J. Chromatogr. B 2012, 893-894:157.
10. Corona G., Elia C., Casetta B., Frustaci S., Toffoli G. Clin. Chim. Acta 2011, 412:358.
11. Hou W., Watters J.W., McLeod H.L. J. Chromatogr. B 2004, 804:263.
12. Kuppens I., Van Maanen M.J., Rosing H., Schellens J., Beijnen J.H. Biomed. Chromatogr. 2004, 19:355.
13. Zhao X., Zhao Y., Geng L., Li X., Wang X., Liu Z., Wang D., Bi K., Chen X. J. Chromatogr. B 2011, 879:3721.
14. Zhao M., Su M., Lin X., Luo Y., He H., Cai C., Tang X. Pharm. Res. 2010, 27:1687.
15. U.S. Food And Drug Administration, Guidance for Industry Bioanalytical Method Validation, , 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
16. Baker S.D., Sparreboom A., Verweij J. Clin. Pharmacokinet. 2006, 45:235.
17. Engels F.K., Loos W.J., van der Bol J.M., de Bruijn P., Mathijssen R.H.J., Verweij J., Mathot R.A.A. Clin. Cancer Res. 2011, 17:353.
18. de Graan A.J.M., Lancaster C.S., Obaidat A., Hagenbuch B., Elens L., Friberg L.E., de Bruijn P., Hu S., Gibson A.A., Bruun G.H. Clin. Cancer Res. 2012, 18:4433.
19. Baker S.D., Zhao M., Lee C.K.K., Verweij J., Zabelina Y., Brahmer J.R., Wolff A.C., Sparreboom A., Carducci M.A. Clin. Cancer Res. 2004, 10:1976.